【摘要】 【目的】评价赫赛汀(Herceptin)联合泰素(TaxotereTAX)剂量密集化疗方法治疗人类表皮生长因子受体2(HER2)过表达晚期乳腺癌的临床价值。【方法】将60例HER2过表达的晚期乳腺癌病人随机分成两组,并同时应用HT(赫赛汀+泰素)方案化疗。其中A组(n=30)患者泰素采用剂量密集的每周给药方案为90mg/m2;B组(n=30)应用常规三周给药方案为175mg/m2。【结果】60例患者可评价客观缓解率(RR)A组和B组分别为73.3%和46.7%,肿瘤进展时间(TTP)分别为10个月和6个月,中位生存期(MedianSurvivalTime,MST)分别为21个月和13个月,两组相比较差异均有显著性(均P<0.01)。且A组毒副作用发生率低于B组。【结论】赫赛汀联合泰素剂量密集化疗治疗HER2过表达的晚期乳腺癌能明显提高临床疗效。更多还原

【Abstract】 [Objective]To investigate the therapeutic effects of recombinant Herceptin and TAX with low dose density chemotherapeutic regimens on patients with HER-2 overexpressing advanced breast carcinoma.[Methods]Sixty patients with HER-2 overexpressing advanced breast carcinoma were randomly divided into two groups. All the patients were treated with the chemotherapeutic regimens of Herceptin combined with TAX. ①Low dose density chemotherapy group(group A), 30 patients received herceptin combined with TAX 90 mg/m2, repeated weekly. ②Routinely treated group (group B), 30 patients were administered routinely with herceptin combined with TAX 175 mg in 3 weeks cycle.[Results]The objective response rate (ORR) in group A was 70%, and that in group B was 46.7 %. The time of tumor progression(TTP) in group A was 10 months , and that in group B was 6 months. The median survival time(MST) in group A was 21 months, and that in group B was 13 months. The toxicity was lower in group A than in group B.[Conclusion]The treatment of Herceptin and TAX with low dose density therapeutic regimens is effective for patients with HER-2 overexpressing advanced breast carcinoma.更多还原